INSULIN DEGLUDEC — NEW GENERATION OF LONGACTING BASAL INSULIN ANALOG (literature review and own data)

Authors

  • Khyzhnyak O. O. SI «V. Danilevsky Institute of Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Karachentsev Yu. I. SI «V. Danilevsky Institute of Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Ostroverkhova G. V. A/S Novo Nordisk Ukraine
  • Gogitidze T. G. SI «V. Danilevsky Institute of Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Seliukova N. Yu. SI «V. Danilevsky Institute of Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Nikolaiev R. S. SI «V. Danilevsky Institute of Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Manskaya K. G. SI «V. Danilevsky Institute of Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2017.4.08

Keywords:

Diabetes Mellitus type 1, Diabetes Mellitus type 2, insulin therapy, basal insulin, insulin degludec.

Abstract

The use of first generation basal insulin analogues has certain limitations due to their pharmacokinetic and pharmacodynamic properties, relatively high risk of hypoglycemia and influence on the patient’s body weight, and require a strict dosage regimens associated with lifestyle limitations. Insulin degludec (Tresiba®) is a new basal insulin with an ultra-long action (up to 42 h), low variability, stable blood glucose concentration during 24 hours and provides effective glycemic control. A pharmacokinetic and pharmacodynamic profile of insulin degludec confirms its slow and continuous absorption in once daily administration, ensures the achievement of glycemic target between meals and during the night. Compared with the group of patients receiving insulin glargine, the average daily basal, average daily bolus and total daily doses of insulin degludec decrease by 14 %, 10 % and 11 %. A stable 24-hour effect of lowering blood glucose and a low hypoglycemia risk allow the flexible dosing of insulin degludec (interval between injections from 8 up to 40 hours) without deterioration of glycemic control, in contrast to other basal insulin, including insulin analogues. This flexibility in prescribing the dose in combination with an effective once-daily administration make insulin degludec a more convenient basal insulin and allow to improve the adherence of patients with Diabetes Mellitus type 1 and 2 to the treatment. In general, the clinical benefits of robust glycemic control, the risk reduction of night hypoglycemia and a more flexible dosing regimen of insulin degludec, overcome the psychological barriers associated with the onset of basal insulin therapy and achieve the restoration of carbohydrates metabolism in patients with Diabetes Mellitus.

References

Nosek L, et al. IDF 2011 21st World Congress: Abstract Book, Dubai, 2011: 474.

Holman RR, Paul SK, Bethel MA, et al. N Engl J Med 2008; 59: 1577-1589.

Nathan DM, Cleary PA, Backlund J-YC, et al. N Engl J Med. 2005; 353: 2643-2653.

American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care 2014;37: S14-S80.

Inzucchi SE, Bergenstal RM, Buse JB, et al. Diabetes Care 2012; 35: 1364-1379.

Brown JB, Nichols GA, Perry A. Diabetes Care 2004; 27: 1535-1540.

Khunti K, Vora J, Davies M. Prim Care Diabetes 2014; 8: 57-63.

Gul'chij MV, et al. Diabet. Ozhyrinnja. Metabolichnyj syndrom 2014;4: 91-98.

Peyrot М, et al. Diabetes 2011;60(1): A225.

Brod M, Barnett AH, Rana A, Peyrot M. Diabetes 2012; 61(1A): LB7.

Brod M, Christensen T, Thomsen TL, Bushnell DM. Value in Health 2011; 14(5): 665-671.

Frier BM. Diabetes Metab Res Rev 2008; 24: 8-92.

Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Diabet Med J Br Diabet Assoc 2012; 29: 682-689.

Ashwell SG, Bradley C, Stephens JW, et al. Diabetes Care 2008; 31: 1112-1117.

Heise T, Nosek L, Rønn BB, et al. Diabetes 2004; 53: 1614-1620.

Smith-Palmer J, Fajardo-Montañana C, Pollock RF, et al. J Med Econ. 2012; 15: 977-986.

Heise T, Pieber TR. Diabetes Obes Metab 2007; 9(5): 648-659.

Klein O, Lynge J, Endahl L, et al. Diabetes Obes Metab 2007; 9(3): 290-299.

Heise T, Nosek L, Ronn BB, et al. Diabetes 2004; 53(6): 1614-1620.

Hermansen K. Diabetes Care 2006;29(6): 1269-1274.

Rosenstock J, Davies M, Home PD, et al. Diabetologia 2008; 51(3): 408-416.

Monami M, Marchionni N, Mannucci E. Diabetes Obes Metab 2009; 11(4): 372-378.

Monami M, Marchionni N, Mannucci E. Diab Res Clin Pract 2008; 81(2): 184-189.

Plank J, Bodenlenz M, Sinner F, et al. Diabetes Care 2005; 28(5): 1107-1112.

Albright ES, Desmond R, Bell DSH. Diabetes Care 2004; 27: 632-633.

Ashwell SG, Gebbie J, Home PD. Diabet Med 2006; 23: 46-52.

Dhatariya K,Yeong J. Diabetologia 2014;53: S390.

European Medicines Agency. Insulin detemir. 2015, available at : http://www.ema.europa.eu/docs/en_GB/document_library/EPAR-Product_Information/human/000528/WC500036662.pdf.

European Medicines Agency. Insulin glargine. 2015, available at : http://www.ema.europa.eu/docs/en_GB/document_library/EPAR-Product_Information/human/000284/WC500036082.pdf.

Klein O, Lynge J, Endahl L, et al. Diabetes Obes Metab 2007; 9: 290-299.

Jonassen I, Havelund S, Hoeg-Jensen T, et al. Pharm Res 2012; 29: 2104-2114.

Kurtzhals P, Heise T, Strauss HM, et al. Diabetologia 2011; 54: S426.

Unnikrishnan AG, Bantwal G, Sahay RK. J Assoc Physicians India 2014; 62: 15-20.

Nishimura E, Sørensen AR, Hansen BF, et al. Diabetologia 2010; 53(1): 388-389.

Heise T, Hövelmann U, Nosek L, et al. Diabetologia 2011; 54(1): 425.

Heise T, Nosek L, Bøttcher SG, et al. Diabetes Obes Metab 2012; 14(10): 944-950.

Koehler G, Treiber G, Wutte A, et al. Diabetes Obes Metab 2014; 16(1): 57-62.

Zinman B, Philis-Tsimikas A, Cariou B, et al. Diabetes Care 2012; 35(12): 2464-2471.

Garber AJ, King AB, Prato SD, et al. Lancet 2012; 379(9825): 1498-1507.

Heller S, Buse J, Fisher M, et al. Lancet 2012;379(9825): 1489-1497.

Meneghini L, Atkin SL, Gough SCL, et al. Diabetes Care 2013; 36(4): 858-864.

Mathieu C, Hollander P, Miranda-Palma B, et al. J Clin Endocrinol Metabol 2013; 98(3): 1154-1162.

Onishi Y, Iwamoto Y, Yoo SJ, et al. J Diabetes Invest 2013; 4(6): 605-612.

Heise T, Nosek L, Bøttcher SG, et al. Diabetes Obes Metab 2012; 14(10): 944-950.

Heise T, Hermanski L, Nosek L, et al. Diabetes Obes Metab 2012; 14(9): 859-864.

US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry: Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention (Draft guidance). Clinical/Medical. 2008, availableat: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071624.pdf

Gough SCL, Bhargava A, Jain R, et al. Diabetes Care. 2013; 36: 2536-2542.

Ratner RE, Gough SCL, Mathieu C, et al. Diabetes Obes Metab. 2013; 15: 175-184.

Koehler G, Heller S, Korsatko S, et al. Diabetologia 2014; 57: 40-49.

Bode B, Heise T, Pieber T, et al. Diabetologia 2013; 56: S423.

Meneghini L, Harris S, Evans M, et al. Diabetologia 2013; 56: S419.

Freemantle N, Meneghini L, Christensen T, et al. Diabet Med. 2013; 30: 226-232.

Home PD, Meneghini L, Wendisch U, et al. Diabet Med 2012; 29: 716-720.

Rodbard H, Cariou B, Zinman B, et al. Diabetes 2013; 62: A237-A238.

Buse JB, Vilsbøll T, Thurman J, et al. Diabetes Care 2014; 37: 2926-2933.

Gough SCL, Bode B, Woo V, et al. Lancet Diabetes Endocrinol 2014; 2: 885-893.

Downloads

Published

2017-10-30

How to Cite

Хижняк, О. О., Караченцев, Ю. І., Островерхова, Г. В., Гогітідзе, Т. Г., Селюкова, Н. Ю., Ніколаев, Р. С., & Манська, Е. Г. (2017). INSULIN DEGLUDEC — NEW GENERATION OF LONGACTING BASAL INSULIN ANALOG (literature review and own data). Problems of Endocrine Pathology, 62(4), 64-77. https://doi.org/10.21856/j-PEP.2017.4.08

Most read articles by the same author(s)

<< < 1 2 3 4 > >>